FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:34-42 January 4, 1996 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Schizophrenia is an often severe and disabling disorder that usually begins in late adolescence or early adulthood. The essential features of this illness are a variable array of symptoms, such as delusions, hallucinations, disorganized or impoverished speech or behavior, flattened affect, and avolition. The onset may be abrupt or insidious; in most instances, however, there is a prodromal phase characterized by gradual social withdrawal, diminished interest in or functioning at school or work, changes in appearance and hygiene, or behavior that is odd or unusual for the person. Although a diagnosis of schizophrenia cannot be made on the basis of . . . [Full Text of this Article]

Drugs Used to Treat Schizophrenia

Antipsychotic Drugs

            Risperidone

            Clozapine

            Dosage

            Adverse Effects

Other Drugs Used in the Treatment of Schizophrenia

            Lithium

            Benzodiazepines

            Anticonvulsant Drugs

            Antidepressant Drugs

            Antiparkinsonian Drugs

Maintenance Treatment

Long-Acting, Injectable Antipsychotic Drugs

Conclusions

Source Information

From the Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, N.Y., and the Department of Psychiatry, Albert Einstein College of Medicine, Bronx, N.Y.

Address reprint requests to Dr. Kane at the Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, 75-59 263rd St., Glen Oaks, NY 11004.

References

This article has been cited by other articles:

• Kane, J. M., Leucht, S. (2008). Unanswered Questions in Schizophrenia Clinical Trials. Schizophr Bull 34: 302-309 [Full Text]  
• Nasrallah, H. A., Lasser, R. (2006). Improving patient outcomes in schizophrenia: achieving remission.. J Psychopharmacol 20: 57-61 [Abstract]  
• la Fougere, C., Meisenzahl, E., Schmitt, G., Stauss, J., Frodl, T., Tatsch, K., Hahn, K., Moller, H.-J., Dresel, S. (2005). D2 Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A 123I-Iodobenzamide SPECT Study. JNM 46: 1028-1033 [Abstract] [Full Text]  
• Conley, R. R., Kelly, D. L., Lambert, T. J., Love, R. C. (2005). Comparison of Clozapine Use in Maryland and in Victoria, Australia. Psychiatr. Serv. 56: 320-323 [Abstract] [Full Text]  
• Rosenheck, R. A. (2005). Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator. Psychiatr. Serv. 56: 85-92 [Full Text]  
• Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E. C., Caroff, S., Corwin, J., Davis, L., Douyon, R., Dunn, L., Evans, D., Frecska, E., Grabowski, J., Graeber, D., Herz, L., Kwon, K., Lawson, W., Mena, F., Sheikh, J., Smelson, D., Smith-Gamble, V. (2003). Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial. JAMA 290: 2693-2702 [Abstract] [Full Text]  
• Sohler, N. L., Walkup, J., McAlpine, D., Boyer, C., Olfson, M. (2003). Antipsychotic Dosage at Hospital Discharge and Outcomes Among Persons With Schizophrenia. Psychiatr. Serv. 54: 1258-1263 [Abstract] [Full Text]  
• Carpenter, W. T. Jr., Appelbaum, P. S., Levine, R. J. (2003). The Declaration of Helsinki and Clinical Trials: A Focus on Placebo-Controlled Trials in Schizophrenia. Am. J. Psychiatry 160: 356-362 [Abstract] [Full Text]  
• Goff, D. C. (2002). A 23-Year-Old Man With Schizophrenia. JAMA 287: 3249-3257 [Full Text]  
• Weijer, C. (2000). The Ethical Analysis of Risk. J Law Med Ethics 28: 344-361  
• Lieberman, J. A., Golden, R., Stroup, S., McEvoy, J. (2000). Drugs of the Psychopharmacological Revolution in Clinical Psychiatry. Psychiatr. Serv. 51: 1254-1258 [Full Text]  
• Rhoades, D. R. (2000). Schizophrenia: A Review for Family Counselors. The Family Journal 8: 258-266 [Abstract]  
• Kapur, S., Zipursky, R., Jones, C., Shammi, C. S., Remington, G., Seeman, P. (2000). A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy. Arch Gen Psychiatry 57: 553-559 [Abstract] [Full Text]  
• Waserman, J., Criollo, M. (2000). Subjective Experiences of Clozapine Treatment by Patients With Chronic Schizophrenia. Psychiatr. Serv. 51: 666-668 [Abstract] [Full Text]  
• Carpenter, W. T. Jr., Buchanan, R. W., Kirkpatrick, B., Lann, H. D., Breier, A. F., Summerfelt, A. T. (1999). Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks. Am. J. Psychiatry 156: 412-418 [Abstract] [Full Text]  
• Carpenter, W. T. Jr., Buchanan, R. W., Kirkpatrick, B., Breier, A. F. (1999). Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia. Am. J. Psychiatry 156: 299-303 [Abstract] [Full Text]  
• Fujian Song, (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65-71 [Abstract]